Brinzolamide: Difference between revisions
m Protected "Brinzolamide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{Brinzolamide}} | |||
{{CMG}}; {{AE}} {{SS}} | |||
'''''For patient information about Brinzolamide, click [[Brinzolamide (patient information)|here]].''''' | |||
{{SB}} AZOPT<sup>®</sup> | |||
==Overview== | |||
| | '''Brinzolamide''' (trade name '''Azopt''', [[Alcon]] Laboratories, Inc.) is a [[carbonic anhydrase inhibitor]] used to lower intraocular pressure in patients with open-angle [[glaucoma]] or ocular hypertension. | ||
| | ==Category== | ||
| | |||
| | Category:Carbonic anhydrase inhibitors;Ethers;Thienothiazines;Sulfones;Sulfonamides;Amines;Cardiovascular Drugs | ||
| | |||
| | ==FDA Package Insert== | ||
| | |||
| | ====AZOPT (brinzolamide) suspension ==== | ||
| | |||
| | ''' [[Brinzolamide indications and usage|Indications and Usage]]''' | ||
| | '''| [[Brinzolamide dosage and administration|Dosage and Administration]]''' | ||
| | '''| [[Brinzolamide dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
| | '''| [[Brinzolamide contraindications|Contraindications]]''' | ||
| | '''| [[Brinzolamide warnings and precautions|Warnings and Precautions]]''' | ||
| | '''| [[Brinzolamide adverse reactions|Adverse Reactions]]''' | ||
| | '''| [[Brinzolamide drug interactions|Drug Interactions]]''' | ||
'''| [[Brinzolamide use in specific populations|Use in Specific Populations]]''' | |||
'''Brinzolamide''' is a [[carbonic anhydrase]] | '''| [[Brinzolamide overdosage|Overdosage]]''' | ||
'''| [[Brinzolamide description|Description]]''' | |||
'''| [[Brinzolamide clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Brinzolamide nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[Brinzolamide clinical studies|Clinical Studies]]''' | |||
'''| [[Brinzolamide how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[Brinzolamide patient counseling information|Patient Counseling Information]]''' | |||
'''| [[Brinzolamide labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
[[Carbonic anhydrase]] (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP). | |||
AZOPT® (brinzolamide ophthalmic suspension) 1% contains brinzolamide, an inhibitor of [[carbonic anhydrase]] II (CA-II). Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated [[intraocular pressure]] is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. | |||
==References== | ==References== | ||
{{reflist|2}} | |||
{{Antiglaucoma preparations and miotics}} | {{Antiglaucoma preparations and miotics}} | ||
[[Category:Carbonic anhydrase inhibitors]] | [[Category:Carbonic anhydrase inhibitors]] | ||
[[Category:Ethers]] | |||
[[Category:Thienothiazines]] | |||
[[Category:Sulfones]] | |||
[[Category:Sulfonamides]] | |||
[[Category:Amines]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] | |||
Revision as of 14:56, 26 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Brinzolamide, click here.
Synonyms / Brand Names: AZOPT®
Overview
Brinzolamide (trade name Azopt, Alcon Laboratories, Inc.) is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Category
Category:Carbonic anhydrase inhibitors;Ethers;Thienothiazines;Sulfones;Sulfonamides;Amines;Cardiovascular Drugs
FDA Package Insert
AZOPT (brinzolamide) suspension
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).
AZOPT® (brinzolamide ophthalmic suspension) 1% contains brinzolamide, an inhibitor of carbonic anhydrase II (CA-II). Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.